Company Description
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma.
The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021.
Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
| Country | United States |
| Founded | 2020 |
| IPO Date | Feb 4, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Ron Bentsur |
Contact Details
Address: 1 Bridge Plaza, Suite 275 Fort Lee, New Jersey 07024 United States | |
| Phone | 201 614 3150 |
| Website | nuvectis.com |
Stock Details
| Ticker Symbol | NVCT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001875558 |
| CUSIP Number | 67080T108 |
| ISIN Number | US67080T1088 |
| Employer ID | 86-2405608 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ron Bentsur M.B.A. | Co-Founder, Chairman, Chief Executive Officer and President |
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive Vice President, Chief Scientific and Business Officer |
| Shay Shemesh | Co-Founder, Executive Vice President, Chief Development and Operations Officer |
| Michael Carson CPA | Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 5, 2025 | 10-Q | Quarterly Report |
| Aug 5, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 8-K | Current Report |
| May 9, 2025 | 8-K | Current Report |
| May 9, 2025 | 424B5 | Filing |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 25, 2025 | 10-K | Annual Report |